CARIBOU BIOSCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.98 USD | -0.25% |
|
-0.75% | -30.54% |
| Apr. 05 | Sector Update: Health Care Stocks Lean Higher Pre-Bell Friday | MT |
| Apr. 04 | Caribou Gets FDA Clearance For Phase 1 Testing of CB-010 Cell Therapy in Lupus Patients | MT |
Financials (USD)
| Sales 2024 * | 9.54M | Sales 2025 * | 9.73M | Capitalization | 359M |
|---|---|---|---|---|---|
| Net income 2024 * | -157M | Net income 2025 * | -207M | EV / Sales 2024 * | 37.7 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 37 x |
| P/E ratio 2024 * |
-2.23
x | P/E ratio 2025 * |
-1.92
x | Employees | 158 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 89.86% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | -0.25% | ||
| 1 week | -0.75% | ||
| Current month | -22.57% | ||
| 1 month | -23.90% | ||
| 3 months | -24.91% | ||
| 6 months | +4.46% | ||
| Current year | -30.54% |
1 week
3.78
4.21
1 month
3.785.62
Current year
3.788.33
1 year
3.448.59
3 years
3.4432.65
5 years
3.4432.65
10 years
3.4432.65
| Managers | Title | Age | Since |
|---|---|---|---|
Rachel Haurwitz
FOU | Founder | 38 | 11-10-27 |
Jason O’Byrne
DFI | Director of Finance/CFO | 54 | 21-02-08 |
Steven Kanner
CTO | Chief Tech/Sci/R&D Officer | 65 | 17-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 55 | 21-03-31 | |
Scott Braunstein
BRD | Director/Board Member | 60 | 21-05-31 |
| Director/Board Member | 59 | 21-11-07 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 6.97% | 2 M€ | -25.75% | ||
| 0.61% | 16 M€ | -6.73% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-23 | 3.98 | -0.25% | 930,742 |
| 24-04-22 | 3.99 | +3.64% | 1,384,845 |
| 24-04-19 | 3.85 | -1.53% | 1,713,612 |
| 24-04-18 | 3.91 | 0.00% | 1,415,632 |
| 24-04-17 | 3.91 | -2.49% | 1,998,823 |
Delayed Quote Nasdaq, April 23, 2024 at 04:00 pm EDT
More quotes
Caribou Biosciences, Inc. is a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It is engaged in developing transformative therapies for patients with devastating diseases. Its genome-editing platform, including its Cas12a chRDNA technology, enables precision to develop cell therapies that are armored to potentially improve antitumor activity. Its pipeline includes three clinical-stage allogeneic cell therapies from its chimeric antigen receptor (CAR)-T (CAR-T) cell platform targeting the treatment of hematologic malignancies. CB-010 is the lead product candidate from its allogeneic CAR-T cell therapy platform and is being evaluated in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). Its second product candidate, CB-011, is being evaluated in patients with relapsed or refractory multiple myeloma (r/r MM) in the CaMMouflage phase I trial. CB-012 is its third product candidate.
Calendar
2024-05-06
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
3.98
USD
Average target price
20
USD
Spread / Average Target
+402.51%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -30.54% | 359M | |
| +3.13% | 43.43B | |
| +49.00% | 41.69B | |
| +8.49% | 41.31B | |
| -10.82% | 27.14B | |
| +8.26% | 25.28B | |
| -23.69% | 18.47B | |
| +32.83% | 12.59B | |
| +1.58% | 12.33B | |
| +6.63% | 11.03B |
- Stock Market
- Equities
- CRBU Stock
